Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
Stéphanie Baillif,
Pascal Staccini,
Michel Weber,
Marie-Noëlle Delyfer,
Yannick Le Mer,
Vincent Gualino,
Laurence Collot,
Pierre-Yves Merite,
Catherine Creuzot-Garcher,
Laurent Kodjikian,
Pascale Massin
Affiliations
Stéphanie Baillif
Department of Ophthalmology, Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, 30 Voie Romaine, 06000 Nice, France
Pascal Staccini
Research Unit RETINES (Risks, Epidemiology, Territories, Information and Education for Health), Université Côte d’Azur, Faculté de Médecine, 28 Avenue de Valombrose, CEDEX 2, 06107 Nice, France
Michel Weber
Department of Ophthalmology, Centre Hospitalier Universitaire de Nantes, 44000 Nantes, France
Marie-Noëlle Delyfer
Department of Ophthalmology, Bordeaux University Hospital, 33000 Bordeaux, France
Yannick Le Mer
Department of Ophthalmology, A. de Rothschild Ophthalmologic Foundation, 75019 Paris, France
Vincent Gualino
Clinique Honoré Cave, Department of Ophthalmology, 82000 Montauban, France
Laurence Collot
Centre Médico-Chirurgical de Chaumont, 17 Avenue des États-Unis, 52000 Chaumont, France
Pierre-Yves Merite
Centre D’ophtalmologie, 44 Avenue de Lattre de Tassigny, 13090 Aix-en-Provence, France
Catherine Creuzot-Garcher
Department of Ophthalmology, Dijon University Hospital, 14 Rue Gaffarel, 21000 Dijon, France
Laurent Kodjikian
Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, 69002 Lyon, France
Pascale Massin
Ophthalmic Centre of Breteuil, 14 avenue de Breteuil, 75007 Paris, France
To assess anatomical and functional outcomes after switching from dexamethasone implant (DEXi) to fluocinolone acetonide implant (FAci) in 113 diabetic macular edema eyes, a multicentric retrospective observational study was conducted. Seventy-five eyes (73.5%) were switched 1–8 weeks after their last DEXi. The mean best-corrected visual acuity improved to 59.8 letters at month 4 and remained stable during the follow-up. The mean central macular thickness (CMT) significantly decreased during the follow-up, with a minimum of 320.9 μm at month 3. The baseline CMT was higher in eyes that received the last DEXi >8 weeks versus p p = 0.009), a longer time between the last DEXi and the first FAci (p = 0.035), and a high baseline CMT (p = 0.003) were risk factors for additional treatments. The mean intraocular pressure was 8 weeks before the switch. Switching from DEXi to FAci in DME is effective and safe. A short time between the last DEXi and the first FAci reduced CMT fluctuations and the need for early additional treatments.
